Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP730354.RABE4mWEszoeB7Qt4GGPUjNTMvfCV9JoAuBhcQNftx-bo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP730354.RABE4mWEszoeB7Qt4GGPUjNTMvfCV9JoAuBhcQNftx-bo130_assertion type Assertion NP730354.RABE4mWEszoeB7Qt4GGPUjNTMvfCV9JoAuBhcQNftx-bo130_head.
- NP730354.RABE4mWEszoeB7Qt4GGPUjNTMvfCV9JoAuBhcQNftx-bo130_assertion description "[Taken together, the results from this study indicate that p300 may be a promising molecular therapeutic target through the modulation of cellular sensitivity to doxorubicin in bladder cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP730354.RABE4mWEszoeB7Qt4GGPUjNTMvfCV9JoAuBhcQNftx-bo130_provenance.
- NP730354.RABE4mWEszoeB7Qt4GGPUjNTMvfCV9JoAuBhcQNftx-bo130_assertion evidence source_evidence_literature NP730354.RABE4mWEszoeB7Qt4GGPUjNTMvfCV9JoAuBhcQNftx-bo130_provenance.
- NP730354.RABE4mWEszoeB7Qt4GGPUjNTMvfCV9JoAuBhcQNftx-bo130_assertion SIO_000772 21935574 NP730354.RABE4mWEszoeB7Qt4GGPUjNTMvfCV9JoAuBhcQNftx-bo130_provenance.
- NP730354.RABE4mWEszoeB7Qt4GGPUjNTMvfCV9JoAuBhcQNftx-bo130_assertion wasDerivedFrom befree-20140225 NP730354.RABE4mWEszoeB7Qt4GGPUjNTMvfCV9JoAuBhcQNftx-bo130_provenance.
- NP730354.RABE4mWEszoeB7Qt4GGPUjNTMvfCV9JoAuBhcQNftx-bo130_assertion wasGeneratedBy ECO_0000203 NP730354.RABE4mWEszoeB7Qt4GGPUjNTMvfCV9JoAuBhcQNftx-bo130_provenance.